- Home
- RARE vs FIBK Comparison
RARE vs FIBK Comparison
Compare RARE & FIBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- FIBK
- Stock Information
- Founded
- RARE 2010
- FIBK 1879
- Country
- RARE United States
- FIBK United States
- Employees
- RARE N/A
- FIBK N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- FIBK Major Banks
- Sector
- RARE Health Care
- FIBK Finance
- Exchange
- RARE Nasdaq
- FIBK Nasdaq
- Market Cap
- RARE 3.2B
- FIBK 3.5B
- IPO Year
- RARE 2014
- FIBK 2010
- Fundamental
- Price
- RARE $33.00
- FIBK $32.59
- Analyst Decision
- RARE Strong Buy
- FIBK Buy
- Analyst Count
- RARE 15
- FIBK 7
- Target Price
- RARE $87.00
- FIBK $35.29
- AVG Volume (30 Days)
- RARE 1.4M
- FIBK 886.1K
- Earning Date
- RARE 11-04-2025
- FIBK 10-29-2025
- Dividend Yield
- RARE N/A
- FIBK 5.80%
- EPS Growth
- RARE N/A
- FIBK 3.95
- EPS
- RARE N/A
- FIBK 2.37
- Revenue
- RARE $630,598,000.00
- FIBK $953,700,000.00
- Revenue This Year
- RARE $19.65
- FIBK $9.45
- Revenue Next Year
- RARE $23.65
- FIBK $2.45
- P/E Ratio
- RARE N/A
- FIBK $13.68
- Revenue Growth
- RARE 20.63
- FIBK 0.26
- 52 Week Low
- RARE $25.81
- FIBK $22.95
- 52 Week High
- RARE $53.04
- FIBK $36.77
- Technical
- Relative Strength Index (RSI)
- RARE 52.70
- FIBK 56.36
- Support Level
- RARE $29.36
- FIBK $31.38
- Resistance Level
- RARE $35.95
- FIBK $32.61
- Average True Range (ATR)
- RARE 1.60
- FIBK 0.84
- MACD
- RARE -0.36
- FIBK 0.11
- Stochastic Oscillator
- RARE 60.79
- FIBK 87.50
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About FIBK First Interstate BancSystem Inc. (DE)
First Interstate BancSystem Inc is a financial holding company. It is the parent company of First Interstate Bank, a community bank offering a range of internet, mobile, and other banking and financial services throughout Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. It delivers a range of financial products and services to both retail and commercial customers in industries like agriculture, construction, education, energy, governmental services, healthcare, mining, professional services, retail, tourism, and wholesale trade. It generates majority of income from interest charged on loans, and interest and dividends earned on investments.